Status:
RECRUITING
Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
Lead Sponsor:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborating Sponsors:
Hôpital d'instruction des armées Sainte-Anne
Conditions:
Macular Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration \[AMD\], diabetic edematous maculopathy or r...
Detailed Description
In order to reduce the frequency of injections in the so-called sub-optimal patients, a "new generation" anti-VEGF will arrive on the market with higher concentrations of active ingredients with a hig...
Eligibility Criteria
Inclusion
- Patient aged 18 or over;
- Patient with an indication for Aflibercept 8mg/0.07mL (EYLEA 8mg)
- Naive or switched patient, i.e. so-called suboptimal responder to anti-VEGF with high injection frequencies
- Patient with rights to social security
- Having given free and informed consent before any participation in research.
Exclusion
- Pregnant or breastfeeding woman
- Patient under legal protection (guardianship, curatorship, etc.) or legal protection
- Patient with significant astigmatism distorting the IOP values in applanation
- Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the study objectives
Key Trial Info
Start Date :
July 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06893965
Start Date
July 8 2025
End Date
July 1 2027
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Military Hopsital of Sainte Anne
Toulon, Var, France, 83000